It would be great if it did, but we’ve made great strides in a lot of non-solid tumors. They are much more targetable, it is easier to get a small molecule to the problem cells. Admittedly, some tumors like GBM without a single mass remain death sentences - but a lot of blood cancers are much better than they were 20 years ago.